Menu
← Oncology Approval Tracker
FDA DECISION ·
Balversa
erdafitinib · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic urothelial carcinoma with an FDA test-confirmed susceptible FGFR3 alteration and progression after at least one systemic treatment line. It is not recommended for patients eligible for, but not previously treated with, a PD-1 or PD-L1 inhibitor.
LAMPGEN ANALYSIS
Why it matters
The traditional approval revised the earlier accelerated indication, including a shift from FGFR2 or FGFR3 to qualifying FGFR3 alterations.
What research teams should watch
Check the actual FGFR report and checkpoint therapy history, and schedule phosphate and ophthalmic monitoring.
PRIMARY RECORDS